Streetbeat News

NRBO

NeuroBo Pharmaceuticals, Inc.

https://www.neurobopharma.com

Industry

Biotechnology

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported a Q2 EPS of $(1.85), significantly missing the analyst consensus estimate of $(1.12) by 65.18%. This represents a 12233.33% decrease compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:15 pm

NeuroBo Pharmaceuticals has completed enrollment for the Single Ascending Dose (SAD) part of its Phase 1 trial for the obesity treatment DA-1726. No significant issues were encountered, allowing for an accelerated start to the Multiple Ascending Dose (MAD) part. Top-line data for SAD is expected in Q3 2024, and MAD data in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:04 pm

NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge have announced a joint research agreement to develop a long-acting, once-monthly formulation of DA-1726 for obesity treatment. The collaboration will leverage ImmunoForge's ELP platform technology to significantly increase the drug's half-life. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:23 pm

NeuroBo Pharmaceuticals has announced a joint research agreement with Dong-A ST Co. Ltd. and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for the treatment of obesity.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:22 pm

NeuroBo Pharmaceuticals shares are trading higher after the company signed an exclusive license agreement providing MThera Pharma Co. with the rights to NB-01.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:04 pm

NeuroBo Pharmaceuticals has signed an exclusive license agreement with MThera Pharma Co., granting them rights to NB-01.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:03 pm

Zacks Small-Cap Research has given NeuroBo Pharmaceuticals (NRBO) a price valuation of $22. This valuation could influence investor sentiment and trading activity for NRBO in the short term.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 6:13 pm

NeuroBo Pharmaceuticals shares are trading higher following the announcement of the dosing of the first patient in the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 4:31 pm

NeuroBo Pharmaceuticals has dosed the first patient in the MAD Part 2 of its Phase 1 trial for DA-1726, an obesity treatment. Top-line data for Part 1 is expected in Q3 2024, and for Part 2 in Q1 2025. A planned Part 3 will assess weight loss at 24 weeks. The company has secured $70M in financing to fund ongoing clinical development.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:08 pm

The article highlights recent insider transactions in three penny stocks: Nanophase Technologies, Nuvation Bio, and NeuroBo Pharmaceuticals. Insider buying can indicate confidence in the company's prospects.

Portfolio Pulse from Avi Kapoor

June 26, 2024 | 12:48 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.